open access

Vol 5, No 4 (2009)
Review paper
Published online: 2009-07-30
Get Citation

Some problems associated with substitution of original chemical and biotechnological medicines by their equivalents

Włodzimierz Bialik
Onkol. Prak. Klin 2009;5(4):148-156.

open access

Vol 5, No 4 (2009)
REVIEW ARTICLES
Published online: 2009-07-30

Abstract

Substitution of traditional chemical medicines by their generics is widely accepted, however, in some cases deep consideration should be involved. Original biotechnological medicines - due to their extremely complicated structure and inability to copy manufacturing procedures by other producers that can lead to differences in product identity and quality - should not be automatically replaced by biosimilars. Scientific, technological and legal issues have been discussed to legitimize such statements.

Abstract

Substitution of traditional chemical medicines by their generics is widely accepted, however, in some cases deep consideration should be involved. Original biotechnological medicines - due to their extremely complicated structure and inability to copy manufacturing procedures by other producers that can lead to differences in product identity and quality - should not be automatically replaced by biosimilars. Scientific, technological and legal issues have been discussed to legitimize such statements.
Get Citation

Keywords

medicines substitution; biotechnology; biotech medicines; epoetins; growth factors; biosimilars

About this article
Title

Some problems associated with substitution of original chemical and biotechnological medicines by their equivalents

Journal

Oncology in Clinical Practice

Issue

Vol 5, No 4 (2009)

Article type

Review paper

Pages

148-156

Published online

2009-07-30

Bibliographic record

Onkol. Prak. Klin 2009;5(4):148-156.

Keywords

medicines substitution
biotechnology
biotech medicines
epoetins
growth factors
biosimilars

Authors

Włodzimierz Bialik

References (17)
  1. Kayser O, Muller RH. Biotechnologia farmaceutyczna. PZWL, Warszawa 2003: 76–87.
  2. Nightingale CH. Quality evaluation of generic clarithromycins from 13 countries, Clin. Drug Invest. 2000: 582–585.
  3. Augustynowicz SZ. ceną nikt nie wygra. Rynek Zdrowia. 2008; 11: 26–28.
  4. Ciupis M. Mały Indeks Leków Medycyny Praktycznej. Wydawnictwo Medycyna Praktyczna, Kraków 2008.
  5. Kaliszan R, Janicki S. Janicki S. Biorównoważność leków Farm Pol. 2001; 10: 456–462.
  6. Nowicki M, Zimmer-Nowicka J. Biofarmaceutyki oryginalne i leki biopodobne — co należy o nich wiedzieć, by zapewnić bezpieczeństwo leczenia. Onkologia w Praktyce Klinicznej. 2007; 3: 120–127.
  7. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncology. 2007: 1–9.
  8. Schellekens H. Biopharmaceuticals and biosimilars, unraveling the complexity. EJHP Practice. 2006; 12: 13.
  9. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology (Carlton). 2006; 11(4): 341–346.
  10. Nelson DI, Cox MM. Principles of biochemistry. W.H. Freeman and Co. W.H. Freeman and Co., New York 2008: 113–182.
  11. Schellekens H. When biotech proteins go off-patent. Trends Biotechnol. 2004; 22(8): 406–410.
  12. Gaps in the quality of and potential safety of biosimilar epoetins in the developing world: and international safety. 2008.
  13. Schellekens H. Follow-on biologics: challenges of the 'next generation'. Nephrology Dialysis Transplantation. 2005; 20(suppl_4): iv31–iv36.
  14. Casadevall N, Rossert J. Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol. 2005; 18(3): 381–387.
  15. http://www.emea.europa.eu/pdfs/human/pcwp/ /7456206en.pdf.
  16. Nowicki M. Czy automatyczna substytucja biofarmaceutyków może być bezpieczna? Służba Zdrowia. 2008; 30: 26–28.
  17. http://www.emea.europa.eu/pdfs/human/biosimilar/3132905en.pdf.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl